Lv7
3440 积分 2023-10-14 加入
Effect of resmetirom or placebo in NASH (MASH) fibrosis patients with<5% or≥5% weight loss and/or on baseline GLP-1 therapy in the MAESTRO-NASH 52-week serial liver biopsy study
9天前
已关闭
Discovery and evaluation of SIPI11594: a novel mitochondrial pyruvate carrier inhibitor with anti-hair loss efficacy
17天前
已完结
Design, synthesis and biological evaluation of novel cyano-cinnamate derivatives as mitochondrial pyruvate carrier inhibitors
17天前
已完结
Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection
19天前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
25天前
已完结
Discovery of the first isoform-specific sGC activator: Selective activation of GC-1 by runcaciguat
1个月前
已关闭
NO- and Heme-Independent sGC Activators, Runcaciguat and Nurandociguat, as New Treatment Options for CKD: From Bench to Bedside
1个月前
已关闭
Mrs2-mediated mitochondrial magnesium uptake is essential for the regulation of MCU-mediated mitochondrial Ca2+ uptake and viability
1个月前
已完结
Enhanced Mitochondrial Mrs2-Mg 2+ Signaling Drives Mitochondrial Dysfunction in Pulmonary Arterial Hypertension Rats
1个月前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2个月前
已完结
皖公网安备34019202002308
